World Heart Federation Roadmap for Hypertension – A 2021 Update

Abstract

screening and of out-of-office blood pressure measurements; the strengthening of primary care and a greater focus on task sharing and team-based care; the delivery of people-centred care and stronger patient and carer education; and the facilitation of adherence to treatment. All of the above are dependent upon the availability and effective distribution of good quality, evidencebased, inexpensive BP-lowering agents.

Nationwide Initiation of Cardiovascular Risk Treatments During the COVID-19 Pandemic in France: Women on a Slippery Slope?

“…Regarding hypertension, no specific recommendation on the use of telehealth services for the screening was mentioned in the latest recommendations from the societies of Hypertension. Only an international consensus from the World Heart Federation was published ( 19 ). This position paper remained very general and reported telehealth experiences more in the management of already diagnosed hypertension than in the screening.…”

2021 World Health Organization guideline on pharmacological treatment of hypertension: Policy implications for the region of the Americas

“…During the last several years, non-governmental organizations such as Resolve to Save Lives, 33 World Heart Federation, 34 Lancet Commission on Hypertension, 35 and the World Hypertension League (WHL) 4 have also produced position statements and ‘calls to action’ on the clinical management of hypertension at a population level ( Table 3 ). These non-governmental positions complement the new WHO hypertension guideline by helping to identify and address barriers to hypertension control and by aligning health care professionals with the need for systematic public health approaches to control hypertension.…”

Blood Pressure and Stroke: A Review of Sex- and Ethnic/Racial-Specific Attributes to the Epidemiology, Pathophysiology, and Management of Raised Blood Pressure

“…Optimal treatment combinations (required by most patients) are not identified for black, South Asian or patients from East Asia. 147 While the CREOLE trial 140 indicates that the combination of amlodipine with either hydrochlorothiazide or perindopril is superior to perindopril plus hydrochlorothiazide in reducing 24-hour BP among black patients from sub-Saharan Africa with hypertension, trials with hard outcomes such as cardiovascular morbidity and mortality are required for a clear recommendation for each major ethnic/racial group. Regarding optimal BP thresholds and targets for different ethnic/racial groups, current randomized evidence suggests that the treatment effects of different BP targets on cardiovascular events were similar for different ethnicities/races (Table S3).…”

“…141,150 Other strategies to improve prevention and control of hypertension at the individual level include efforts towards increased awareness and self-care skills, availability of, and adherence to, quality antihypertensive therapies, availability of university health coverage and access to health care. 147 Health care–related reasons for poor hypertension control include accepted standards and goals in hypertension treatment and control, physician education and familiarity with therapeutic options, physician-to-patient ratio or nurse-to-patient ratio, antihypertensive regime complexity, provider-patient interaction, and adequate patient follow-up. 151 Broader efforts to investigate the challenges in effective implementation of evidence-based care are likely to address social and ethnic/racial differences in hypertension treatment and control.…”